Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Modulight receives pilot production order worth 1.5 MUSD

MODUAnalyst Comment16.09.2026 klo 09.23
Antti SiltanenAnalyst
Discuss

Summary

  • Modulight announced a 1.5 MUSD pilot production order from a US neuroscience customer, marking a significant step in its product development projects towards commercialization.
  • The order involves semiconductor laser products for measuring brain activity, transitioning from development to pilot production, which will increase delivery volumes.
  • This order supports Modulight's growth outlook for 2026–2027, with deliveries starting immediately and continuing over the next 12 months, aligning with existing revenue forecasts.
  • The customer has committed to advance payments, reducing Modulight's working capital requirements, which is beneficial given the company's current unprofitability.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 9/16/2026 at 7:35 am EEST.

Modulight announced on Tuesday that it has received a pilot production order worth 1.5 MUSD from its American customer in the field of neuroscience. In our view, the order is significant relative to the company's current scale and provides much-needed concrete evidence of the progress of long-term product development projects toward the commercial phase. The order will be delivered and invoiced gradually over the next 12 months. Our forecasts already include expectations of successes similar to this news, so we do not see any immediate pressure to change our forecasts.

Long-term product development cooperation is bearing fruit

The order concerns semiconductor laser products used in a neuroscience application, which the customer utilizes in its technology being developed for measuring brain activity. According to the press release, Modulight has been working with the US-based customer in question for several years. The new order marks a transition from product development to pilot production, which will multiply the delivery volumes compared to before. We consider this step forward important, as Modulight's investment story relies heavily on the company's extensive early-stage project pipeline maturing into the commercial phase over time and starting to generate scalable revenue. In our view, the application area related to the combination of neuroscience and artificial intelligence is also an interesting addition alongside the company's more traditional cancer and ophthalmology applications.

The order supports the growth outlook for 2026–2027

The order of approximately 1.3 MEUR is large on Modulight's scale, as our forecast for the full-year 2026 revenue is 7.2 MEUR and 9.8 MEUR for the following year. According to the press release, deliveries will begin immediately and continue on a monthly basis for the next 12 months, meaning the bulk of the project will take place next year. The customer has committed to advance payments that cover the materials needed for the ordered products. This reduces the working capital requirement associated with the order, which is welcome, as Modulight is still unprofitable. Since our forecasts already include expectations of similar successes, the order does not cause an immediate need to change our figures, despite the positive news.

 

Login required

This content is only available for logged in users

Create account

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Read more on company page

Key Estimate Figures23.08.

202526e27e
Revenue7.17.29.8
growth-%72.6 %1.2 %36.4 %
EBIT (adj.)-4.6-4.9-3.8
EBIT-% (adj.)-65.8 %-69.1 %-38.6 %
EPS (adj.)-0.11-0.11-0.07
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.151.423.9

Forum discussions

Here are Antti’s comments on the offer received by Modulight Modulight announced on Tuesday that it has received a USD 1.5 million pilot production...
4 hours ago
by Sijoittaja-alokas
4
The share price has been hovering around 1.02 for a while now, and just for fun, I’ve had my 1,500 shares up for sale at 1.055–1.10 for a couple...
21 hours ago
by Tero Hautala
4
Modulight Oyj Press Release This is actually significant news, considering the nature of the order. Moving to pilot production with a long-term...
21 hours ago
6
A bit late again in getting around to diving into the H1 report and Orsila’s interview. For me, this has been a quite interesting investment...
8/26/2026, 6:09 PM
by PerusPiensijoittaja
7
Well, yeah, if I remember correctly, Modulight’s strategy has relied on biomedicine starting from 2014, so in that respect, there haven’t been...
8/25/2026, 12:58 PM
by Antti Siltanen
5
Fortunately, the company seems to take the adequacy of its cash reserves genuinely seriously. Interest in the company is so non-existent and...
8/25/2026, 12:06 PM
2
Must have been a challenging task to deploy such a huge pile of money efficiently. Orsila just mentioned in the latest interview that when making...
8/25/2026, 11:06 AM
by NOKNOK
0